Depression Experience Journal: A Computer-Based Intervention for Families Facing Childhood Depression - 09/08/11
, Nicole Eldridge Marcus, Ph.D., Carolyn Kinnamon, B.A., Joseph Gonzalez-Heydrich, M.D.ABSTRACT |
Objective |
This study tested the feasibility and safety of a computer-based application for families facing childhood depression. The Depression Experience Journal (EJ) is a psychoeducational intervention based on a narrative model involving the sharing of personal stories about childhood depression.
Method |
Semistructured interviews assessed Depression EJ feasibility and safety. Thirty-eight primary caretakers of children with depression (one caretaker per patient) used the EJ during a psychiatric hospitalization. Assessment of feasibility and safety was measured before EJ use and 2 to 4 weeks afterward.
Results |
Results revealed that the EJ was safe and useful for decreasing social isolation, increasing hope, increasing understanding of familial feelings about childhood depression, and fostering positive reactions in caretakers.
Conclusions |
Computer-based interventions hold significant promise in providing a new manner of psychosocial support to families facing child and adolescent psychiatric illnesses.
Le texte complet de cet article est disponible en PDF.Key Words : prevention, pediatric, computer, safety, depression
Plan
| This work was supported by a grant from the Sidney A. Swensrud Foundation. The authors thank Lara Kay, Jennifer Scharping, Erin Collins, Kathryn Skitt, Rebecca Casey, Jeffrey DeMaso, and Rebecca Waters, as well as all the families who contributed to the Depression Experience Journal. The authors thank William R. Beardslee, M.D., for his support. |
|
| Disclosure: Dr. Gonzalez-Heydrich has received research support from Abbott Laboratories, Pfizer, Cyberonics, and Janssen Pharmaceutica Research Foundation; has been a consultant to McNeil Consumer and Specialty Pharmaceuticals, Novartis, GlaxoSmithKline, and Eli Lilly; and has been on the speaker’s bureau of Novartis, Pfizer, and Abbott Laboratories and on the advisory board of McNeil Consumer and Specialty Pharmaceuticals and Cyberonics. The other authors have no financial relationships to disclose. |
Vol 45 - N° 2
P. 158-165 - février 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
